Rimegepant Production Cost Reports

The report provides a detailed analysis essential for establishing a rimegepant production plant. It encompasses all critical aspects necessary for rimegepant production, including the cost of rimegepant production, rimegepant plant cost, rimegepant production costs, and the overall rimegepant production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a rimegepant production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Rimegepant is a calcitonin gene-related peptide (CGRP) receptor antagonist. It is utilised as an acute treatment for migraine attacks with or without aura in adults. It provides rapid relief from headache pain, photophobia, phonophobia, and nausea. It works within 2 hours via a single 75 mg oral disintegrating tablet that bypasses swallowing issues common in acute migraine.

It also functions effectively for preventive therapy in episodic migraine, where every-other-day 75 mg dosing significantly reduces monthly migraine days by 4-5 compared to placebo. It shows compatibility with anti-CGRP monoclonal antibodies without notable drug interactions. Its dual indication, favourable tolerability (primarily mild nausea), and oral formulation make it a versatile option compared with triptans or injectables.

The market for rimegepant is fuelled by growing cases of migraine around the globe. Its FDA approval for acute treatment and episodic prevention as a CGRP antagonist offering fast relief without triptan vasoconstriction risks contributes to its demand. The strong clinical data showing superior efficacy over placebo, and expanding access via patient assistance programs for novel non-opioid therapies fuels its market. The industrial rimegepant procurement is affected by high premium pricing, limited generic competition due to patents and supply chain reliance on specialised API synthesis. The regional reimbursement variations and inventory management for fluctuating demand in outpatient settings further impact its market dynamics.

Raw Material for Rimegepant Production

According to the rimegepant production plant project report, the key raw materials used in the production of rimegepant include diketone precursor, chiral hydrogenation catalyst, reducing agents, and silyl protecting reagents.

Production Process of Rimegepant

The extensive rimegepant production cost report consists of the following major industrial production process:

1. From diketone precursor: The synthesis of Rimegepant involves two separate advanced fragments. The first part is prepared by enantioselective reduction and functionalisation of a diketone to give a cycloheptapyridine alcohol, which is then converted to an azide-bearing intermediate. The other part is formed through reductive amination and urea formation to yield a p-nitrocarbamate intermediate containing the imidazopyridine and piperidine moieties. These two intermediates are joined by a nucleophilic substitution. Subsequently, the azide in the combined intermediate is reduced to an amine, completing the rimegepant API structure. The synthesised rimegepant is finally converted to its hemisulfate salt by dissolving the base compound in ethanol and water to give rimegepant sulfate.

Rimegepant is a small-molecule CGRP receptor antagonist with the molecular formula C28H28F2N6O3 and molecular weight of 534.56 g/mol. It has a complex structure with piperidine, imidazopyridine, and difluorophenyl rings linked via amide and carbamate moieties. It appears as a white to off-white solid with low water solubility but good oral bioavailability. It has collision cross-sections around 230-238 Ų for [M+H]⁺and [M+Na]⁺ions in mass spectrometry. Its specific stereochemistry supports its formulation as an orally disintegrating tablet for rapid migraine relief. All these physical and chemical properties contribute to its high potency at CGRP receptors while minimising off-target effects.